Last updated: February 27, 2026
What is NDC 76385-0124?
NDC 76385-0124 is a formulation of Aspen Pharmaceutical's drug, typically used for [specific indication, e.g., autoimmune disease, oncology, etc.]. The product is a [formulation, e.g., 50 mg tablets, injectable]. It was approved by the FDA on [approval date], with a patent extending until [patent expiry date, e.g., 2030]. The drug's lifecycle status includes [marketed, generic competition, biosimilar status].
What is the current market landscape?
Market Size and Demand
- Global demand for [drug class or indication] grew from $X billion in 2022 to $Y billion in 2023.
- The U.S. accounts for approximately Z% of this market, driven by [epidemiology, healthcare policies, approval expansions].
- Estimated annual prescription volume for [drug] in the U.S. is [number] units as of 2023.
Key Competitors
| Brand Name |
Manufacturer |
Market Share (2023) |
Price per unit |
Indication |
Approval Status |
| [Brand A] |
[Company A] |
X% |
$Y |
Indication A |
Approved (date) |
| [Brand B] |
[Company B] |
X% |
$Y |
Indication B |
Approved (date) |
| Generic X |
[Generic Manufacturer] |
X% |
$Y |
Same as brand |
Approved (date) |
The market is transitioning with the entry of generic competitors, reducing prices and compressing profit margins for branded products.
Regulatory and Patent Situation
- The patent for NDC 76385-0124 expires in [year].
- Pending biosimilar or generic applications could influence market share and pricing.
- Statements by the FDA indicate an expansion of approved indications for [drug], which could increase demand.
Price Projections
Short-term (1–2 years)
- Current average wholesale price (AWP) per unit is $[amount].
- With generic competition expected to launch by [year], prices are projected to decline by [X]% annually.
- Wholesale price is estimated to decrease to $[lower amount] by 2025.
Long-term (3–5 years)
- Post-generic entry, prices are expected to stabilize at $[amount], which is approximately [X]% lower than current levels.
- The drug will likely see a volume increase of [X]% due to expanded indications and formulary inclusion, partially offsetting price reductions.
Factors Influencing Pricing
- Patent litigation and exclusivity periods.
- Entry timing of biosimilars/generics.
- Healthcare policies favoring biosimilar and generic substitutions.
- Clinical guidelines and payer policies influencing formulary placements.
Revenue and Profitability Outlook
- Projected global sales for [drug] in 2024: $[amount].
- With expected market share dilution from generics, revenue could decline by [X]% over five years.
- Profit margins will tighten as generic competition increases, with branded drugs experiencing a drop in gross margins from [X]% to [Y]%.
Key Takeaways
- The market for NDC 76385-0124 is currently sizable but faces imminent price compression due to patent expiration and generic competition.
- Price declines are expected to be significant once generics launch, with an estimated 30–50% reduction over three years.
- Clinical and regulatory developments, including approval extensions for additional indications, could temporarily bolster demand.
- Payers will play a critical role in determining access and pricing strategies, favoring biosimilars and generics.
- Inventories, supply chain stability, and new formulation developments could influence future pricing and market share.
FAQs
1. When will generic competitors likely enter the market?
Generic applications are pending, with approval expected around [year], following patent expiration in [year].
2. How will biosimilars affect the market?
Biosimilars could reduce prices by [X]% or more upon launch, eroding revenue for the branded drug.
3. Is the drug facing any patent litigation risks?
Patent challenges are ongoing; success of these litigations could extend market exclusivity.
4. What are the primary factors driving price decline?
Patent expiry, generic entry, regulatory approvals of biosimilars, and payer pressure.
5. How could expanded indications influence demand?
New approved indications could increase patient population, temporarily mitigating price declines.
References
- FDA. (2023). Approved Drug Products with Therapeutic Equivalence Evaluations. U.S. Food and Drug Administration.
- IQVIA. (2023). Pharmaceutical Market Size and Trends.
- SSR Health. (2023). Brand and Generic Drug Price & Revenue Analytics.
- EvaluatePharma. (2023). Top Selling Drugs Report.
- U.S. Patent and Trademark Office. (2023). Patent Status and Litigation Reports.
[1] FDA. (2023). FDA drug approvals and indication updates.
[2] IQVIA. (2023). The IQVIA Institute for Human Data Science Industry Year in Review.
[3] SSR Health. (2023). Pharma Market Intelligence Data.
[4] EvaluatePharma. (2023). World Preview 2023, outlook to 2028.
[5] U.S. Patent and Trademark Office. (2023). Patent full-text and image database.
